Literature DB >> 10090179

The clinical spectrum of severe septic bursitis in northwestern Spain: a 10 year study.

C García-Porrúa1, M A González-Gay, D Ibañez, M J García-País.   

Abstract

OBJECTIVE: To assess the clinical and microbiological characteristics of septic bursitis in those cases that required treatment at the hospital during the past 10 years in a northwestern area of Spain.
METHODS: The charts of all patients diagnosed as having septic bursitis at Hospital Xeral-Calde, Lugo, Spain, from October 1987 through September 1997 were reviewed based on published criteria and graded according to severity.
RESULTS: Sixty-nine patients diagnosed with definite and 6 with probable septic bursitis met the criteria for severe septic bursitis. Sixty-two were male (82.7%). The mean age at the time of diagnosis was 51 years. The most frequently involved sites were olecranon (47%) and prepatellar (44%) bursae. Among predisposing factors, the presence of prepatellar bursitis was correlated with a job that involved frequent trauma on the bursae. The main clinical and laboratory findings were cellulitis and/or erythema (94.7%), fever (77.3%), and leukocytosis (72%). Noninflammatory synovial fluid (SF, < 2,000 leukocytes/mm3) was observed in 4/32 (12.5%) cases. Positive SF cultures were obtained in 69 of 75 patients (92%). Staphylococcus aureus was the most common pathogen (84%). Blood cultures were positive in 12 of 62 patients (19.4%). Three patients had osteomyelitis. This complication was associated with a longer delay to diagnosis from the onset of symptoms (> 3 weeks vs 9.3+/-13.3 days for the group as a whole). Apart from these 3 cases, overall outcome was excellent.
CONCLUSION: Severe septic bursitis is a common disease. Local trauma is the most common risk factor for this infection. Although the most common pathogen is S. aureus, other pathogens such as Brucella abortus play an important role in this infection in our area.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090179

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Supra-patellar bursitis in a neonate.

Authors:  S Amuchou Singh; Kanya Mukhopadhyay; Anil Narang
Journal:  Indian J Pediatr       Date:  2002-01       Impact factor: 1.967

Review 2.  Interventional therapeutic procedures to treat degenerative and inflammatory musculoskeletal conditions: state of the art.

Authors:  Vito Chianca; Davide Orlandi; Carmelo Messina; Domenico Albano; Angelo Corazza; Santi Rapisarda; Grazia Pozzi; Roberto Luigi Cazzato; Giovanni Mauri; Enzo Silvestri; Luca Maria Sconfienza
Journal:  Radiol Med       Date:  2019-03-04       Impact factor: 3.469

Review 3.  Olecranon bursitis: a systematic overview.

Authors:  John R Blackwell; Bruce A Hay; Alexander M Bolt; Stuart M Hay
Journal:  Shoulder Elbow       Date:  2014-05-06

4.  A Randomized Trial Among Compression Plus Nonsteroidal Antiinflammatory Drugs, Aspiration, and Aspiration With Steroid Injection for Nonseptic Olecranon Bursitis.

Authors:  Joon Yub Kim; Seok Won Chung; Joo Hak Kim; Jae Hong Jung; Gwang Young Sung; Kyung-Soo Oh; Jong Soo Lee
Journal:  Clin Orthop Relat Res       Date:  2015-10-13       Impact factor: 4.176

5.  Clinical characteristics and outcomes of septic bursitis.

Authors:  Sarah B Lieber; Mary Louise Fowler; Clara Zhu; Andrew Moore; Robert H Shmerling; Ziv Paz
Journal:  Infection       Date:  2017-05-29       Impact factor: 3.553

6.  Prepatellar Brucella melitensis bursitis: case report and literature review.

Authors:  R Traboulsi; I Uthman; S S Kanj
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

Review 7.  [Treatment of traumatic lesions of the bursa olecrani and chronic bursitis olecrani].

Authors:  D Saul; K Dresing
Journal:  Oper Orthop Traumatol       Date:  2017-06       Impact factor: 1.154

8.  Recent developments in septic bursitis.

Authors:  Jennifer A Hanrahan
Journal:  Curr Infect Dis Rep       Date:  2013-10       Impact factor: 3.725

9.  Evaluation of current treatment regimens for prepatellar and olecranon bursitis in Switzerland.

Authors:  S F Baumbach; H Wyen; C Perez; K-G Kanz; I Uçkay
Journal:  Eur J Trauma Emerg Surg       Date:  2012-11-08       Impact factor: 3.693

10.  Endoscopic treatment of prepatellar bursitis.

Authors:  Yu-Chih Huang; Wen-Lin Yeh
Journal:  Int Orthop       Date:  2010-06-04       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.